UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2495) 2495
female (2487) 2487
ovarian neoplasms - enzymology (2021) 2021
science & technology (1773) 1773
life sciences & biomedicine (1635) 1635
oncology (1146) 1146
ovarian neoplasms - pathology (1139) 1139
ovarian cancer (1028) 1028
cell line, tumor (698) 698
middle aged (597) 597
animals (593) 593
ovarian neoplasms - drug therapy (586) 586
ovarian neoplasms - genetics (575) 575
adult (534) 534
aged (441) 441
cancer (438) 438
mice (397) 397
immunohistochemistry (365) 365
tumor cells, cultured (324) 324
ovarian neoplasms - metabolism (317) 317
obstetrics & gynecology (264) 264
prognosis (248) 248
cell biology (247) 247
antineoplastic agents - pharmacology (243) 243
male (238) 238
apoptosis (226) 226
tumors (215) 215
research (213) 213
gene expression regulation, neoplastic (211) 211
proteins (195) 195
apoptosis - drug effects (194) 194
biochemistry & molecular biology (193) 193
gene expression (188) 188
analysis (181) 181
aged, 80 and over (179) 179
neoplasm staging (178) 178
mice, nude (177) 177
ovarian carcinoma (177) 177
transfection (175) 175
research article (174) 174
signal transduction (169) 169
neoplasm invasiveness (165) 165
breast neoplasms - enzymology (164) 164
blotting, western (161) 161
pathology (157) 157
cell proliferation (152) 152
chemotherapy (152) 152
kinases (149) 149
metastasis (149) 149
genetic aspects (146) 146
medicine (144) 144
neoplasms - enzymology (144) 144
abridged index medicus (143) 143
cell proliferation - drug effects (143) 143
cisplatin - pharmacology (143) 143
ovary - enzymology (141) 141
drug resistance, neoplasm (140) 140
rna, messenger - genetics (139) 139
enzymes (138) 138
science & technology - other topics (138) 138
carcinoma - enzymology (137) 137
multidisciplinary sciences (137) 137
breast cancer (136) 136
care and treatment (136) 136
health aspects (132) 132
adenocarcinoma - enzymology (131) 131
phosphorylation (129) 129
development and progression (125) 125
ovarian neoplasms - therapy (122) 122
pharmacology & pharmacy (122) 122
mutation (121) 121
signal transduction - drug effects (120) 120
time factors (120) 120
ovarian neoplasms - diagnosis (119) 119
antineoplastic agents - therapeutic use (117) 117
neoplasms, glandular and epithelial - enzymology (117) 117
science (116) 116
ovarian neoplasms - mortality (115) 115
reverse transcriptase polymerase chain reaction (114) 114
xenograft model antitumor assays (114) 114
hematology, oncology and palliative medicine (111) 111
dose-response relationship, drug (110) 110
enzyme inhibitors - pharmacology (110) 110
neoplasm metastasis (108) 108
biomarkers, tumor - metabolism (107) 107
medicine, research & experimental (106) 106
research & experimental medicine (106) 106
carcinoma, ovarian epithelial (103) 103
rna, messenger - metabolism (102) 102
cystadenocarcinoma, serous - enzymology (99) 99
physiological aspects (99) 99
obstetrics and gynecology (96) 96
biology (94) 94
gene expression regulation, enzymologic (92) 92
adolescent (90) 90
biomarkers, tumor - analysis (89) 89
endocrine system diseases (89) 89
cell survival - drug effects (87) 87
genes (87) 87
cell cycle (86) 86
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2437) 2437
German (53) 53
Chinese (50) 50
Russian (47) 47
Japanese (41) 41
French (13) 13
Italian (9) 9
Polish (9) 9
Czech (3) 3
Spanish (3) 3
Norwegian (2) 2
Portuguese (2) 2
Bulgarian (1) 1
Dutch (1) 1
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer chemotherapy and pharmacology, ISSN 1432-0843, 07/2019, Volume 84, Issue 3, pp. 487 - 499
Enzymes of the cytochrome P450 (CYP) subfamily 3A and 2C play a major role in the metabolism of taxane anticancer agents. While their function in hepatic... 
Intratumoral | Ritonavir | Paclitaxel | Docetaxel | CYP | Review | Journal Article | Medicine & Public Health | Oncology | Cancer Research | Pharmacology/Toxicology | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - drug therapy | Taxoids - pharmacology | Humans | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Male | Breast Neoplasms - enzymology | Female | Antineoplastic Agents - pharmacology | Cytochrome P-450 CYP2C8 - metabolism | Ovarian Neoplasms - drug therapy | Prostatic Neoplasms - drug therapy | Prostatic Neoplasms - pathology | Endometrial Neoplasms - enzymology | Lung Neoplasms - enzymology | Neoplasms - enzymology | Breast Neoplasms - drug therapy | Ovarian Neoplasms - enzymology | Neoplasms - drug therapy | Breast Neoplasms - pathology | Cytochrome P-450 CYP3A - metabolism | Prostatic Neoplasms - enzymology | Endometrial Neoplasms - drug therapy | Endometrial Neoplasms - pathology | Neoplasms - pathology | Antimitotic agents | Protease inhibitors | Proteases | Pharmacy | Cytochrome P-450 | Physiological aspects | Drugstores | Antineoplastic agents | Ovarian cancer | Cytochrome | Enzymes | Cytochrome P450 | Proteinase inhibitors | Taxane | Metabolism | Anticancer properties | Antitumor agents | Lungs | Drug metabolism | Breast | Solid tumors | Taxanes | Prostate | Endometrium | Tumors | Cytochromes P450 | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Journal Article
Molecular and Cellular Biology, ISSN 0270-7306, 10/2003, Volume 23, Issue 19, pp. 6836 - 6848
Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley... 
Biochemistry & Molecular Biology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Neoplasms - metabolism | Prostatic Neoplasms - metabolism | Colonic Neoplasms - virology | Phosphorylation | Adenovirus E1A Proteins - chemistry | Humans | Protein-Serine-Threonine Kinases | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Male | Prostatic Neoplasms - virology | Colonic Neoplasms - metabolism | Breast Neoplasms - metabolism | Neoplasms - virology | Breast Neoplasms - enzymology | Neoplasms - genetics | Ovarian Neoplasms - virology | Adenovirus E1A Proteins - metabolism | Gene Deletion | Adenoviridae - genetics | Female | Ovarian Neoplasms - metabolism | p38 Mitogen-Activated Protein Kinases | Protein Structure, Tertiary | Proto-Oncogene Proteins - metabolism | Cell Line | Prostatic Neoplasms - pathology | Neoplasms - enzymology | Ovarian Neoplasms - enzymology | Breast Neoplasms - virology | Gene Expression Regulation, Enzymologic | Proto-Oncogene Proteins c-akt | Breast Neoplasms - pathology | Colonic Neoplasms - pathology | Prostatic Neoplasms - enzymology | Mitogen-Activated Protein Kinases - genetics | Colonic Neoplasms - enzymology | Adenoviridae - metabolism | Neoplasms - pathology | Apoptosis | Mitogen-Activated Protein Kinases - metabolism | Index Medicus | Cell Growth and Development
Journal Article
The lancet oncology, ISSN 1470-2045, 2011, Volume 12, Issue 9, pp. 852 - 861
Summary Background Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Humans | Middle Aged | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Time Factors | Aged, 80 and over | Cell Differentiation | Carcinoma - drug therapy | Enzyme Inhibitors - adverse effects | Phthalazines - administration & dosage | Administration, Oral | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Enzyme Inhibitors - therapeutic use | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | Canada | Breast Neoplasms - genetics | Carcinoma - genetics | Mutation | Receptor, ErbB-2 - analysis | Piperazines - administration & dosage | Receptors, Estrogen - analysis | Ovarian Neoplasms - mortality | Breast Neoplasms - enzymology | Antineoplastic Agents - adverse effects | Carcinoma - enzymology | Adult | Female | Ovarian Neoplasms - drug therapy | Carcinoma - secondary | Biomarkers, Tumor - analysis | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Treatment Outcome | BRCA1 Protein - genetics | Disease-Free Survival | Phthalazines - therapeutic use | Poly(ADP-ribose) Polymerases - metabolism | Breast Neoplasms - pathology | Breast Neoplasms - mortality | Aged | BRCA2 Protein - genetics | Phthalazines - adverse effects | Care and treatment | Relapse | Gene mutations | Oncology, Experimental | Breast cancer | Research | Cancer | Diseases | Index Medicus
Journal Article
Journal Article
American Journal of Physiology: Cell Physiology, ISSN 0363-6143, 06/2016, Volume 310, Issue 11, pp. C857 - C873
The leucine-rich repeat containing 8A (LRRC8A) protein is an essential component of the volume-sensitive organic anion channel (VSOAC), and using... 
Taurine | Transcription factors | Multidrug resistance | Organic anion channels | Apoptosis | Platinum drugs | Lung Neoplasms - drug therapy | Proto-Oncogene Proteins c-mdm2 - genetics | Caspase 9 - genetics | Caspase 9 - metabolism | Cation Transport Proteins - antagonists & inhibitors | Adenocarcinoma, Bronchiolo-Alveolar - pathology | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Lung Neoplasms - pathology | Tumor Suppressor Protein p53 - genetics | Adenocarcinoma, Bronchiolo-Alveolar - genetics | Ovarian Neoplasms - genetics | Cyclin-Dependent Kinase Inhibitor p21 - genetics | Transfection | Anion Transport Proteins - antagonists & inhibitors | RNA Interference | Time Factors | Cation Transport Proteins - metabolism | Membrane Transport Modulators - pharmacology | Caspase 3 - genetics | Cyclin-Dependent Kinase Inhibitor p21 - metabolism | Female | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Ovarian Neoplasms - drug therapy | Proto-Oncogene Proteins c-mdm2 - metabolism | Adenocarcinoma, Bronchiolo-Alveolar - enzymology | Lung Neoplasms - genetics | A549 Cells | Lung Neoplasms - enzymology | Membrane Proteins - genetics | Down-Regulation | Tumor Suppressor Protein p53 - metabolism | Cell Size | Cisplatin - pharmacology | Anion Transport Proteins - metabolism | Ovarian Neoplasms - enzymology | Signal Transduction - drug effects | Adenocarcinoma, Bronchiolo-Alveolar - drug therapy | Index Medicus | Call for Papers | multidrug resistance | transcription factors | platinum drugs | organic anion channels | taurine | apoptosis
Journal Article
Journal of cellular and molecular medicine, ISSN 1582-1838, 05/2010, Volume 14, Issue 5, pp. 1180 - 1193
Recent reports have suggested that statins induce cell death in certain epithelial cancers and that patients taking statins to reduce cholesterol levels... 
apoptosis | statins | gynaecological cancers | therapy | Therapy | Gynaecological cancers | Statins | Apoptosis | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Cell Biology | Research & Experimental Medicine | Gene Expression Regulation, Enzymologic - drug effects | Lovastatin - pharmacology | Humans | Ovarian Neoplasms - pathology | Uterine Cervical Neoplasms - pathology | Simvastatin - pharmacology | Ovarian Neoplasms - genetics | Lipids - chemistry | Hydroxymethylglutaryl CoA Reductases - metabolism | Water - chemistry | Female | Genital Neoplasms, Female - enzymology | Cell Death - drug effects | Gene Expression Regulation, Neoplastic - drug effects | Genital Neoplasms, Female - genetics | Mevalonic Acid - pharmacology | Pravastatin - pharmacology | Cell Survival - drug effects | Epithelium - drug effects | Epithelium - pathology | Uterine Cervical Neoplasms - enzymology | Uterine Cervical Neoplasms - genetics | Ovarian Neoplasms - enzymology | Drug Synergism | Drug Resistance, Neoplasm - genetics | Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology | Signal Transduction - drug effects | Cell Line, Tumor | Polyisoprenyl Phosphates - pharmacology | Sesquiterpenes - pharmacology | Genital Neoplasms, Female - pathology | Hydroxymethylglutaryl CoA Reductases - genetics | Drug Resistance, Neoplasm - drug effects | Cytochrome | Reductases | Flow cytometry | Genital tract | Toxicity | Clinical trials | Lovastatin | Cell viability | Kinases | Pravastatin | Cancer therapies | Western blotting | Ovarian cancer | Anticancer properties | Proteins | Time dependence | Lipophilic | Signal transduction | Cell activation | Antitumor agents | Mevalonic acid | Enzymatic activity | Cleavage | Endometrium | Incubation | Mortality | Gynecology | Simvastatin | Poly(ADP-ribose) polymerase | Caspase | Tumor cell lines | Cervix | Cholesterol | Studies | Cytochrome c | Antibiotics | Hydrophilicity | Cell death | Cytochromes | Reductase | Oncology | Gene expression | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 01/2015, Volume 16, Issue 1, pp. 87 - 97
Summary Background The poly(ADP-ribose) polymerase inhibitor olaparib has shown antitumour activity in patients with platinum-sensitive, recurrent, high-grade... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Humans | Middle Aged | Ovarian Neoplasms - pathology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - administration & dosage | Ovarian Neoplasms - mortality | Molecular Targeted Therapy | Enzyme Inhibitors - administration & dosage | Ovarian Neoplasms - genetics | Young Adult | Neoplasm Grading | Time Factors | Antineoplastic Agents - adverse effects | Adult | Female | Neoplasms, Cystic, Mucinous, and Serous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Enzyme Inhibitors - adverse effects | Neoplasms, Cystic, Mucinous, and Serous - pathology | Phthalazines - administration & dosage | Drug Administration Schedule | Administration, Oral | Neoplasm Recurrence, Local | Carboplatin - administration & dosage | Neoplasms, Cystic, Mucinous, and Serous - enzymology | Treatment Outcome | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors | Ovarian Neoplasms - enzymology | BRCA1 Protein - genetics | Disease-Free Survival | Administration, Intravenous | Poly(ADP-ribose) Polymerases - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | BRCA2 Protein - genetics | Neoplasms, Cystic, Mucinous, and Serous - mortality | Phthalazines - adverse effects | Relapse | Chemotherapy | Hospitals | Gene mutations | Sugars | Diseases | Cancer | Monosaccharides | Ovarian cancer | Index Medicus
Journal Article